[Clinical importance of the quantification of HIV-1 RNA in cerebrospinal fluid for the diagnosis of HIV encephalitis]. 1998

P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
Service de Virologie, Hôpital Pitié-Salpêtrière, Paris, France.

We evaluated prospectively the HIV-1 RNA level in CSF as a marker of HIV encephalitis diagnosis. 110 HIV-1 infected patients (mean age: 39 years; sex-ratio M/F: 94/16) were tested for HIV-1 RNA in plasma and CSF. Lumbar punctures were performed to explore cognitive deficit, seizure or fever. HIV encephalitis was diagnosed in 15 patients (14%), other CNS disease in 34 (31%), and fever without CNS disease in 61 (55%). HIV-1 RNA was detectable in 93% of the plasma and in 62% of the CSF. No significant difference was observed in CSF HIV-1 RNA between patients with or without HIV encephalitis. CSF HIV-1 RNA was correlated with plasma HIV-1 RNA (p < 0.01), CSF protein (p < 0.01) and CSF white cell counts (p < 0.01). The absence of any significant difference between patients with or without HIV encephalitis, suggests that the CSF HIV-1 RNA level is not a good marker for its diagnosis.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015526 AIDS Dementia Complex A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40) AIDS Encephalopathy,Dementia Complex, AIDS-Related,HIV Dementia,HIV Encephalopathy,HIV-1-Associated Cognitive Motor Complex,HIV-Associated Cognitive Motor Complex,AIDS-Related Dementia Complex,Acquired-Immune Deficiency Syndrome Dementia Complex,Dementia Complex, Acquired Immune Deficiency Syndrome,Encephalopathy, AIDS,Encephalopathy, HIV,HIV-1 Cognitive and Motor Complex,AIDS Encephalopathies,AIDS Related Dementia Complex,Complex, AIDS Dementia,Complex, AIDS-Related Dementia,Dementia Complex, AIDS,Dementia Complex, AIDS Related,Dementia, HIV,Dementias, HIV,Encephalopathies, AIDS,Encephalopathies, HIV,HIV 1 Associated Cognitive Motor Complex,HIV 1 Cognitive and Motor Complex,HIV Associated Cognitive Motor Complex,HIV Dementias,HIV Encephalopathies

Related Publications

P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
March 1998, AIDS (London, England),
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
January 1988, Klinische Wochenschrift,
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
May 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
May 2013, Journal of cellular physiology,
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
January 1997, AIDS (London, England),
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
August 1996, Antiviral therapy,
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
April 2013, AIDS (London, England),
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
December 2000, Journal of acquired immune deficiency syndromes (1999),
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
December 2007, Journal of acquired immune deficiency syndromes (1999),
P Bossi, and S Dupré, and N Dupin, and A Coutellier, and F Bricaire, and C Lubetzki, and C Katlama, and V Calvez
August 2015, Journal of biomedical science,
Copied contents to your clipboard!